Opinion · 29 Jun 2025
Research articlePublished 19 Sep 2022
The anglia regional experience of using PEP-C as palliative chemotherapy in relapsed refractory lymphoma: A multicentre retrospective cohort study.
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
PEP-C (Prednisolone, Etoposide, Procarbazine, and Cyclophosphamide) is an orally administered daily chemotherapy regimen used with palliative intent in relapsed refractory lymphoma. To our knowledge no data on PEP-C has been reported since the original group described the regimen. Here we present a multicentre retrospective cohort reporting our use of PEP-C in 92 patients over an eight-year period. We find that even heavily pretreated lymphoma can respond to PEP-C, particularly low grade lymphoma (including mantle cell) and lymphoma that was sensitive to the previous line of systemic therapy (chemosensitive). These characteristics may help in the selection of patients likely to derive benefit. The median overall survival of patients with chemosensitive lymphoma treated with PEP-C is 217 days. Within the limitations of a retrospective cohort we find that PEP-C is well tolerated: The most common toxicity leading to discontinuation is marrow suppression. We suggest that PEP-C should be considered for patients with relapsed refractory lymphoma in two settings: Firstly, where there is no licensed alternative; and secondly, where the licensed alternative is an intravenous drug and the burden of frequent hospital visits for intravenous drug administration would be too great.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Clinical Oncology and Cancer Research.
Opinion · 29 Jun 2025
Molecular Biomarkers for Early Detection and Prognosis of Breast Cancer
Commentary · 29 Jun 2025
Targeted Therapy in Non-Small Cell Lung Cancer: Current Landscape and Future Directions
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical Oncology and Cancer Research
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Anna Santarsieri”
- BylineArticles whose byline prints “Annabel M Follows”
- BylineArticles whose byline prints “Simon J Bulley”
- BylineArticles whose byline prints “James Russell”
- BylineArticles whose byline prints “Benjamin J Uttenthal”
- BylineArticles whose byline prints “George A Follows”
- BylineArticles whose byline prints “Isabel C Lentell”
- BylineArticles whose byline prints “Andrew Hodson”
